19:40 , Apr 14, 2017 |  BC Week In Review  |  Clinical News

Personal Genome Service Genetic Health Risk (GHR) test regulatory update

FDA approved 23andMe's PGS Genetic Health Risk (GHR) test to assess genetic risk for 10 diseases and conditions. The approved indications are Parkinson’s disease (PD), late-onset Alzheimer’s disease (AD), celiac disease, alpha-1 antitrypsin (AAT; A1AT;...
18:34 , Mar 8, 2017 |  BC Innovations  |  Translation in Brief

Up to eleven

Factor XI inhibitors may not only have safety advantages over more established anticoagulants, but could come with blood pressure-lowering benefits as well. A Science Translational Medicine study from Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and Johannes Gutenberg...
19:07 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Mouse and rat studies suggest inhibiting Factor XI could help treat arterial hypertension and consequent tissue damage. In a mouse model of arterial hypertension, an antisense oligonucleotide targeting Factor XI decreased blood pressure and...
20:40 , Feb 17, 2017 |  BC Week In Review  |  Company News

Ionis, Bayer deal

Ionis will receive a $75 million milestone payment from Bayer tied the development of anticoagulants IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx, both Factor XI antisense inhibitor. The partners share rights to IONIS-FXIRx under a 2015 deal...
22:50 , Feb 14, 2017 |  BC Extra  |  Company News

Ionis gets $75M milestone in Bayer anticoagulant deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is to receive a $75 million milestone payment from Bayer AG (Xetra:BAYN) tied to milestones in the development of Factor XI antisense inhibitors IONIS-FXIRx (BAY 2306001) and IONIS-FXI-LRx. The partners share...
20:22 , Dec 9, 2016 |  BC Week In Review  |  Clinical News

SPK-9001: Additional Ph I/II data

Data from the first 9 hemophilia B patients in an open-label, dose-escalation, U.S. and Australian Phase I/II trial showed that a single dose of 5x1011 vg/kg IV SPK-9001 led to an asymptomatic, transient elevation in...
11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

IONIS-FXIRx: Ph II data

A double-blind, Canadian Phase II trial in 43 patients with ESRD receiving hemodialysis showed that 200 and 300 mg doses of subcutaneous IONIS-FXIRx dosed twice weekly for 2 weeks and then once weekly for 10...
07:00 , Sep 29, 2016 |  BC Innovations  |  Product R&D

Safety Factor

Although the advent of Factor Xa inhibitors improved quality of life for many thrombosis patients, the compounds' bleeding risk prevents use in patient populations with certain co-morbidities, and has prompted a handful of companies to...
07:00 , Sep 15, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Factor XIa

Cardiovascular disease INDICATION: Thrombosis In vitro, mouse and rabbit studies suggest an anti-Factor XIa mAb could help treat thrombosis. Screening of an antibody library and mutagenesis of hits identified a mAb that inhibited human Factor XIa activity...
07:00 , Mar 24, 2016 |  BC Innovations  |  Product R&D

Liver-bound

Ionis Pharmaceuticals Inc. is retooling its antisense technology with a sugar-based conjugate that boosts uptake into liver cells. By tapping the power of GalNAc sugars to latch onto hepatocyte receptors, the company believes it can...